A multicenter comparison of [
PET
Tau
[18F]Flortaucipir
[18F]MK6240
[18F]RO948
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
27
10
2020
accepted:
03
05
2021
pubmed:
28
5
2021
medline:
29
6
2021
entrez:
27
5
2021
Statut:
ppublish
Résumé
This study aims to determine whether comparable target regions of interest (ROIs) and cut-offs can be used across [ A total of 1755 participants underwent tau PET using either [ Comparable diagnostic performance (area under the receiver operating characteristic curve [AUC]) was observed between theory- and data-driven ROIs. The theory-defined temporal meta-ROI generally performed very well for all three tracers (AUCs: 0.926-0.996). An SUVR value of approximately 1.35 was a common threshold when using this ROI. The temporal meta-ROI can be used for differential diagnosis of dementia patients with [
Identifiants
pubmed: 34041562
doi: 10.1007/s00259-021-05401-4
pii: 10.1007/s00259-021-05401-4
pmc: PMC8175317
doi:
Substances chimiques
Carbolines
0
tau Proteins
0
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
J09QS3Z3WB
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2295-2305Références
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1–13. https://doi.org/10.1016/j.jalz.2011.10.007 .
doi: 10.1016/j.jalz.2011.10.007
pubmed: 22265587
pmcid: 3266529
Goedert M. Tau filaments in neurodegenerative diseases. FEBS Lett. 2018;592:2383–91. https://doi.org/10.1002/1873-3468.13108 .
doi: 10.1002/1873-3468.13108
pubmed: 29790176
Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–59. https://doi.org/10.1146/annurev.neuro.24.1.1121 .
doi: 10.1146/annurev.neuro.24.1.1121
pubmed: 11520930
Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies-still a challenge. Mol Psychiatry. 2019;24:1112–34. https://doi.org/10.1038/s41380-018-0342-8 .
doi: 10.1038/s41380-018-0342-8
pubmed: 30635637
pmcid: 6756230
Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78:787–800. https://doi.org/10.1002/ana.24517 .
doi: 10.1002/ana.24517
pubmed: 26344059
pmcid: 4900162
Smith R, Puschmann A, Scholl M, Ohlsson T, van Swieten J, Honer M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain. 2016;139:2372–9. https://doi.org/10.1093/brain/aww163 .
doi: 10.1093/brain/aww163
pubmed: 27357347
pmcid: 4995360
Smith R, Scholl M, Widner H, van Westen D, Svenningsson P, Hagerstrom D, et al. In vivo retention of (18)F-AV-1451 in corticobasal syndrome. Neurology. 2017;89:845–53. https://doi.org/10.1212/WNL.0000000000004264 .
doi: 10.1212/WNL.0000000000004264
pubmed: 28754841
pmcid: 5580862
Kuwabara H, Comley RA, Borroni E, Honer M, Kitmiller K, Roberts J, et al. Evaluation of (18)F-RO-948 PET for quantitative assessment of tau accumulation in the human brain. J Nucl Med. 2018;59:1877–84. https://doi.org/10.2967/jnumed.118.214437 .
doi: 10.2967/jnumed.118.214437
pubmed: 30097505
pmcid: 6278898
Pascoal TA, Shin M, Kang MS, Chamoun M, Chartrand D, Mathotaarachchi S, et al. In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240. Alzheimers Res Ther. 2018;10:74. https://doi.org/10.1186/s13195-018-0402-y .
doi: 10.1186/s13195-018-0402-y
pubmed: 30064520
pmcid: 6069775
Betthauser TJ, Cody KA, Zammit MD, Murali D, Converse AK, Barnhart TE, et al. In vivo characterization and quantification of neurofibrillary tau PET radioligand (18)F-MK-6240 in humans from Alzheimer disease dementia to young controls. J Nucl Med. 2019;60:93–9. https://doi.org/10.2967/jnumed.118.209650 .
doi: 10.2967/jnumed.118.209650
pubmed: 29777006
pmcid: 6354223
Cho H, Choi JY, Hwang MS, Kim YJ, Lee HM, Lee HS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol. 2016;80:247–58. https://doi.org/10.1002/ana.24711 .
doi: 10.1002/ana.24711
pubmed: 27323247
Scholl M, Lockhart SN, Schonhaut DR, O’Neil JP, Janabi M, Ossenkoppele R, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971–82. https://doi.org/10.1016/j.neuron.2016.01.028 .
doi: 10.1016/j.neuron.2016.01.028
pubmed: 26938442
pmcid: 4779187
Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539–50. https://doi.org/10.1093/brain/aww023 .
doi: 10.1093/brain/aww023
pubmed: 26936940
Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76:1395–402. https://doi.org/10.1212/WNL.0b013e3182166e96 .
doi: 10.1212/WNL.0b013e3182166e96
pubmed: 21490323
pmcid: 3087406
Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207–18. https://doi.org/10.1016/j.neurobiolaging.2009.07.002 .
doi: 10.1016/j.neurobiolaging.2009.07.002
pubmed: 19660834
Pankov A, Binney RJ, Staffaroni AM, Kornak J, Attygalle S, Schuff N, et al. Data-driven regions of interest for longitudinal change in frontotemporal lobar degeneration. Neuroimage Clin. 2016;12:332–40. https://doi.org/10.1016/j.nicl.2015.08.002 .
doi: 10.1016/j.nicl.2015.08.002
pubmed: 27547726
Vogel JW, Mattsson N, Iturria-Medina Y, Strandberg OT, Scholl M, Dansereau C, et al. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease. Hum Brain Mapp. 2019;40:638–51. https://doi.org/10.1002/hbm.24401 .
doi: 10.1002/hbm.24401
pubmed: 30368979
Chiotis K, Saint-Aubert L, Rodriguez-Vieitez E, Leuzy A, Almkvist O, Savitcheva I, et al. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia. Mol Psychiatry. 2018;23:1666–73. https://doi.org/10.1038/mp.2017.108 .
doi: 10.1038/mp.2017.108
pubmed: 28507319
Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer’s disease. Brain. 2018;141:1517–28. https://doi.org/10.1093/brain/awy059 .
doi: 10.1093/brain/awy059
pubmed: 29538647
pmcid: 5917767
Ishiki A, Okamura N, Furukawa K, Furumoto S, Harada R, Tomita N, et al. Longitudinal assessment of tau pathology in patients with Alzheimer’s disease using [18F]THK-5117 positron emission tomography. PLoS One. 2015;10:e0140311. https://doi.org/10.1371/journal.pone.0140311 .
doi: 10.1371/journal.pone.0140311
pubmed: 26461913
pmcid: 4604169
Sintini I, Martin PR, Graff-Radford J, Senjem ML, Schwarz CG, Machulda MM, et al. Longitudinal tau-PET uptake and atrophy in atypical Alzheimer’s disease. Neuroimage Clin. 2019;23:101823. https://doi.org/10.1016/j.nicl.2019.101823 .
doi: 10.1016/j.nicl.2019.101823
pubmed: 31004914
pmcid: 6475765
Harrison TM, La Joie R, Maass A, Baker SL, Swinnerton K, Fenton L, et al. Longitudinal tau accumulation and atrophy in aging and Alzheimer disease. Ann Neurol. 2019;85:229–40. https://doi.org/10.1002/ana.25406 .
doi: 10.1002/ana.25406
pubmed: 30597624
pmcid: 6579738
Pontecorvo MJ, Devous MD, Kennedy I, Navitsky M, Lu M, Galante N, et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain. 2019;142:1723–35. https://doi.org/10.1093/brain/awz090 .
doi: 10.1093/brain/awz090
pubmed: 31009046
pmcid: 6536847
Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1–15 e1–4. https://doi.org/10.1016/j.jalz.2014.07.003 .
doi: 10.1016/j.jalz.2014.07.003
pubmed: 25443857
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62. https://doi.org/10.1016/j.jalz.2018.02.018 .
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
pmcid: 5958625
Smith R, Scholl M, Leuzy A, Jogi J, Ohlsson T, Strandberg O, et al. Head-to-head comparison of tau positron emission tomography tracers [(18)F]flortaucipir and [(18)F]RO948. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04496-0 .
Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67. https://doi.org/10.1093/brain/aww027 .
doi: 10.1093/brain/aww027
pubmed: 26962052
pmcid: 5006248
Mattsson N, Scholl M, Strandberg O, Smith R, Palmqvist S, Insel PS, et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. EMBO Mol Med. 2017;9:1212–23. https://doi.org/10.15252/emmm.201707809 .
doi: 10.15252/emmm.201707809
pubmed: 28743782
pmcid: 5582410
Geurts P, Ernst D, Wehenkel L. Extremely randomized trees. Mach Learn. 2006;63:3–42.
doi: 10.1007/s10994-006-6226-1
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.
doi: 10.1007/BF00308809
Ossenkoppele R, Rabinovici GD, Smith R, Cho H, Scholl M, Strandberg O, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320:1151–62. https://doi.org/10.1001/jama.2018.12917 .
doi: 10.1001/jama.2018.12917
pubmed: 30326496
pmcid: 6233630
Leuzy A, Smith R, Ossenkoppele R, Santillo A, Borroni E, Klein G, et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.0989 .
Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Knopman DS, Lowe V, et al. Age-specific and sex-specific prevalence of cerebral beta-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. Lancet Neurol. 2017;16:435–44. https://doi.org/10.1016/S1474-4422(17)30077-7 .
doi: 10.1016/S1474-4422(17)30077-7
pubmed: 28456479
pmcid: 5516534
Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer’s disease. Alzheimers Dement. 2017;13:205–16. https://doi.org/10.1016/j.jalz.2016.08.005 .
doi: 10.1016/j.jalz.2016.08.005
pubmed: 27697430
Kotari V, Navitsky M, Southekal S, Kennedy I, Harris T, Lu M, et al. Early tau detection and implications for disease progression. Alzheimer’s Dement. 2019;15:P1614–P5.
doi: 10.1016/j.jalz.2019.06.4839
Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid beta and tau in Alzheimer’s disease: implications for primary prevention. Brain Commun. 2020;2:fcaa007. https://doi.org/10.1093/braincomms/fcaa007 .
doi: 10.1093/braincomms/fcaa007
pubmed: 32140682
pmcid: 7048875
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.
Franzmeier N, Dewenter A, Frontzkowski L, Rubinski A, Neitzel J, Smith R, et al. Connectivity-based modeling of tau pathology spread in Alzheimer’s disease – towards precision medicine.Alzheimers Dement. 2020. https://doi.org/10.1002/alz.040587 .
Fleisher AS, Pontecorvo MJ, Devous MD Sr, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.0528 .
Honer M, Gobbi L, Knust H, Kuwabara H, Muri D, Koerner M, et al. Preclinical evaluation of (18)F-RO6958948, (11)C-RO6931643, and (11)C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease. J Nucl Med. 2018;59:675–81. https://doi.org/10.2967/jnumed.117.196741 .
doi: 10.2967/jnumed.117.196741
pubmed: 28970331
pmcid: 5932750
Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, et al. Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med. 2016;57:1599–606. https://doi.org/10.2967/jnumed.115.171678 .
doi: 10.2967/jnumed.115.171678
pubmed: 27230925
La Joie R, Ayakta N, Seeley WW, Borys E, Boxer AL, DeCarli C, et al. Multisite study of the relationships between antemortem [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer’s disease neuropathology. Alzheimers Dement. 2019;15:205–16. https://doi.org/10.1016/j.jalz.2018.09.001 .
doi: 10.1016/j.jalz.2018.09.001
pubmed: 30347188
Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007;257:80–7. https://doi.org/10.1016/j.jns.2007.01.045 .
doi: 10.1016/j.jns.2007.01.045
pubmed: 17324442
Smith R, Santillo AF, Waldo ML, Strandberg O, Berron D, Vestberg S, et al. (18)F-Flortaucipir in TDP-43 associated frontotemporal dementia. Sci Rep. 2019;9:6082. https://doi.org/10.1038/s41598-019-42625-9 .
doi: 10.1038/s41598-019-42625-9
pubmed: 30988363
pmcid: 6465310
Bevan-Jones WR, Cope TE, Jones PS, Passamonti L, Hong YT, Fryer TD, et al. [(18)F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89:1032–7. https://doi.org/10.1136/jnnp-2017-316402 .
doi: 10.1136/jnnp-2017-316402
pubmed: 28912300
Makaretz SJ, Quimby M, Collins J, Makris N, McGinnis S, Schultz A, et al. Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry. 2018;89:1024–31. https://doi.org/10.1136/jnnp-2017-316409 .
doi: 10.1136/jnnp-2017-316409
pubmed: 28986472
Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M, et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain. 2020;143:2818–30. https://doi.org/10.1093/brain/awaa180 .
doi: 10.1093/brain/awaa180
pubmed: 32671408